You are here

Proceedings of the National Academy of Sciences of the United States of America DOI:10.1073/pnas.0407117101

Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips.

Publication TypeJournal Article
Year of Publication2004
AuthorsHuang, J, Zhu, H, Haggarty, SJ, Spring, DR, Hwang, H, Jin, F, Snyder, M, Schreiber, SL
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue47
Pages16594-9
Date Published2004/11/23
ISSN0027-8424
Abstract

The TOR (target of rapamycin) proteins play important roles in nutrient signaling in eukaryotic cells. Rapamycin treatment induces a state reminiscent of the nutrient starvation response, often resulting in growth inhibition. Using a chemical genetic modifier screen, we identified two classes of small molecules, small-molecule inhibitors of rapamycin (SMIRs) and small-molecule enhancers of rapamycin (SMERs), that suppress and augment, respectively, rapamycin's effect in the yeast Saccharomyces cerevisiae. Probing proteome chips with biotinylated SMIRs revealed putative intracellular target proteins, including Tep1p, a homolog of the mammalian PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumor suppressor, and Ybr077cp (Nir1p), a protein of previously unknown function that we show to be a component of the TOR signaling network. Both SMIR target proteins are associated with PI(3,4)P2, suggesting a mechanism of regulation of the TOR pathway involving phosphatidylinositides. Our results illustrate the combined use of chemical genetics and proteomics in biological discovery and map a path for creating useful therapeutics for treating human diseases involving the TOR pathway, such as diabetes and cancer.

URLhttp://www.pnas.org/cgi/pmidlookup?view=long&pmid=15539461
DOI10.1073/pnas.0407117101
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/15539461?dopt=Abstract